Nature Biotechnology 24, 472 (2006)
doi:10.1038/nbt0406-472
PeoplePaul L. Berns (left) has been appointed Allos Therapeutics' (Westminster, CO, USA) president, CEO and member of the board of directors. He brings close to 15 years of pharmaceutical industry experience to Allos, holding senior management positions at Abbott Laboratories, BASF Pharmaceuticals and Bristol-Myers Squibb. Mr. Berns was most recently president, CEO and a member of the board of directors of Bone Care International. With Mr. Berns' appointment, Michael E. Hart has resigned his positions as president, CEO and CFO, and David C. Clark, the company's controller and treasurer, has been appointed to serve as interim CFO until a permanent replacement is found.
Privately held NascaCell IP (Munich) has announced the appointment of cofounder Michael Blind to the position of CEO. Dr. Blind was previously responsible for research and development activities at NascaCell.
Thomas A. Bologna has been appointed president, CEO and a director of Orchid Cellmark (Princeton, NJ, USA), succeeding Paul Kelly. Mr. Bologna was most recently president and CEO of Quorex Pharmaceuticals, and previously chairman, president and CEO of Ostex International.
Gary W. Coy has been appointed CFO of Amarillo Biosciences (Amarillo, TX, USA) He brings over 30 years of management experience, most recently serving as a financial consultant to the biomedical and real estate industries. Previously, Mr. Coy was chairman and president of Lighthouse Properties.
Ocera Therapeutics (San Diego, CA, USA) has announced the appointment of Joe Davie to its board of directors. Dr. Davie was formerly senior vice president of Biogen's research department, and also served as senior vice president, science and technology at G.D. Searle. He has served on the board of directors of Auxeris Therapeutics, Beyond Genomics, Curis, Inflazyme Pharmaceuticals, Keel Pharmaceuticals, Metaphore Pharmaceuticals, Neogenesis, Stratatech and Targeted Genetics. Ocera also named Karen Church as vice president of regulatory affairs and Caroline LaPlaca as senior director of clinical operations. Dr. Church has more than 30 years of regulatory affairs experience in the biopharmaceutical industry, most recently at Pfizer. Ms. LaPlaca was most recently head of clinical operations at Vical.
VLST Corp. (Seattle, WA, USA) has announced the appointment of Julie M. Eastland as CFO. She joins the company from Dendreon, where she was most recently vice president of strategic planning.
PDL BioPharma (Fremont, CA, USA) has named Andrew Guggenhime senior vice president and CFO. He joins the company from Neoforma, where he served as vice president of corporate development before being promoted to the post of CFO in October 2000. Before joining Neoforma, Mr. Guggenhime was a vice president in the healthcare investment banking group of Merrill Lynch.
ZymoGenetics (Seattle, WA, USA) has elected Judith A. Hemberger to its board of directors. Dr. Hemberger recently retired from Pharmion, where she was a founder, former executive vice president and COO, and a director since its inception in 2000. She also previously served as senior vice president of business development at AVAX Technologies. Dr. Hemberger currently serves on the board of directors of Myogen, Perrigo, PRA International and Renovis.
Doug Janzen has been promoted to president and chief business officer of Cardiome Pharma (Vancouver, BC, Canada). Mr. Janzen joined Cardiome in January 2003, serving as CFO. Before joining the company, he was managing director, health sciences and partner at Sprott Securities, a Toronto-based investment bank. Bob Rieder will continue in his role as Cardiome's CEO, and has been appointed vice-chairman of the board of directors.
NitroMed (Lexington, MA, USA) has announced that Argeris (Jerry) Karabelas, currently chairman of the board of directors, has been appointed interim CEO, succeeding Michael Loberg, who resigned from his position as president, CEO and director of NitroMed. In addition, Kenneth Bate, formerly CFO of Millennium Pharmaceuticals, has been named chief operating officer and CFO, following the departure of Lawrence Bloch as CFO and chief business officer.
Morphotek (Exton, PA, USA) has announced the appointment of Robert Radie as chief business officer and the promotion of Luigi Grasso to senior vice president of R&D. Mr. Radie was most recently senior vice president of strategic projects and planning at Vicuron Pharmaceuticals, and played an integral role in the company's recent acquisition by Pfizer. Dr. Grasso, a cofounder, has served as Morphotek's vice president of research since its inception.
Inotek (Beverly, MA, USA) has named Emma Reeve as vice president and CFO. Ms. Reeve previously served as vice president and CFO for Aton Pharma until its acquisition by Merck. She then joined the Merck Research Laboratories' Boston team as site head of research operations.
The Medicines Company (Parsippany, NJ, USA) has named Glenn Sblendorio executive vice president and CFO. Mr. Sblendorio, who was involved in the original startup planning and served a senior vice president of business development, returns to the company from Eyetech Pharmaceuticals, where he was executive vice president and CFO until Eyetech was acquired by OSI Pharmaceuticals in November 2005. He replaces Steve Koehler, who resigned to take a position with a large pharmaceutical company.
Thomas Williams has been named CSO and vice president of R&D of Exagen Diagnostics (Albuquerque, NM, USA). Dr. Williams previously served as the company's special advisor for molecular pathology. Additionally, he was vice chairman, department of pathology, at the University of New Mexico School of Medicine and director of the Genetics and Cytometry Division at TriCore Reference Laboratories.
|
